- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
3B BlackBio Dx Limited held an investor call regarding its financial results for the third quarter and nine months. Nine-month revenue reached 99.06 Cr, up from 64.80 Cr (excluding Coris last year). The company expects 10-15% top-line growth for the full year, with exports growing 15-20%. Acquired company Coris contributed about 24 Cr in quarterly revenue, including approximately 8.8 Cr from a multi-year HAT contract. Coris is pursuing US FDA approval (estimated 3.12 Cr - 4.16 Cr cost) to tap the US market, a process expected to take 1-2 years. 3B is also developing new sample-to-answer and POC systems, maintaining focus on infectious and oncology diagnostics, and has approximately 190 Cr cash for future acquisitions.